Cargando…

Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?

Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA – infliximab, etanercept, and adalimumab – have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartzman, Sergio, Fleischmann, Roy, Morgan, G James
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833457/
https://www.ncbi.nlm.nih.gov/pubmed/15228615
http://dx.doi.org/10.1186/ar1013
_version_ 1782178390952902656
author Schwartzman, Sergio
Fleischmann, Roy
Morgan, G James
author_facet Schwartzman, Sergio
Fleischmann, Roy
Morgan, G James
author_sort Schwartzman, Sergio
collection PubMed
description Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA – infliximab, etanercept, and adalimumab – have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal antibodies, and etanercept is a soluble protein. The pharmacokinetic and pharmacodynamic properties of each differs significantly from those of the others. All three agents are effective and safe, and can improve the quality of life in patients with RA. Although no direct comparisons are available, clinical trials provide evidence that can be used to evaluate the comparative efficacy of these agents. Infliximab, in combination with methotrexate, has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, prevent joint erosions and joint-space narrowing, and improve physical function for up to 2 years. Etanercept has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, and slow the rate of joint destruction, and might improve physical function. Etanercept is approved with and without methotrexate for patients who have demonstrated an incomplete response to therapy with methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs), as well as for first-line therapy in early RA, psoriatic arthritis, and juvenile RA. Adalimumab relieves the signs and symptoms of RA with and without methotrexate and other DMARDs, decreases total joint score progression, prevents joint erosions and joint-space narrowing in combination with methotrexate, and might improve physical function. When selecting a TNF antagonist, rheumatologists should weigh evidence and experience with specific agents before a decision is made for use in therapy.
format Text
id pubmed-2833457
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28334572010-03-08 Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Schwartzman, Sergio Fleischmann, Roy Morgan, G James Arthritis Res Ther Review Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA – infliximab, etanercept, and adalimumab – have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal antibodies, and etanercept is a soluble protein. The pharmacokinetic and pharmacodynamic properties of each differs significantly from those of the others. All three agents are effective and safe, and can improve the quality of life in patients with RA. Although no direct comparisons are available, clinical trials provide evidence that can be used to evaluate the comparative efficacy of these agents. Infliximab, in combination with methotrexate, has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, prevent joint erosions and joint-space narrowing, and improve physical function for up to 2 years. Etanercept has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, and slow the rate of joint destruction, and might improve physical function. Etanercept is approved with and without methotrexate for patients who have demonstrated an incomplete response to therapy with methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs), as well as for first-line therapy in early RA, psoriatic arthritis, and juvenile RA. Adalimumab relieves the signs and symptoms of RA with and without methotrexate and other DMARDs, decreases total joint score progression, prevents joint erosions and joint-space narrowing in combination with methotrexate, and might improve physical function. When selecting a TNF antagonist, rheumatologists should weigh evidence and experience with specific agents before a decision is made for use in therapy. BioMed Central 2004 2004-06-21 /pmc/articles/PMC2833457/ /pubmed/15228615 http://dx.doi.org/10.1186/ar1013 Text en Copyright ©2004 BioMed Central Ltd
spellingShingle Review
Schwartzman, Sergio
Fleischmann, Roy
Morgan, G James
Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
title Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
title_full Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
title_fullStr Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
title_full_unstemmed Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
title_short Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
title_sort do anti-tnf agents have equal efficacy in patients with rheumatoid arthritis?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833457/
https://www.ncbi.nlm.nih.gov/pubmed/15228615
http://dx.doi.org/10.1186/ar1013
work_keys_str_mv AT schwartzmansergio doantitnfagentshaveequalefficacyinpatientswithrheumatoidarthritis
AT fleischmannroy doantitnfagentshaveequalefficacyinpatientswithrheumatoidarthritis
AT morgangjames doantitnfagentshaveequalefficacyinpatientswithrheumatoidarthritis